Consolidated Financial Results for 1st Quarter of Fiscal 2024
(Reference Data of Consolidated Financial Results)
August 7, 2024
KAKEN PHARMACEUTICAL CO., LTD.
Corporate Communications
Tel: +81-(0)3-5977-5002
1. Summary of Consolidated Financial Statements for 1st Quarter of | Fiscal 2024 | |||||||
(amounts are rounded down to the nearest million Yen) | ||||||||
FY2023 | FY2024 | Change | Revised | Change | ||||
FY2023 | Plan | |||||||
1Q | 1Q | Amount | % | Amount | % | |||
FY2024 | ||||||||
Net sales | 18,150 | 72,044 | 18,254 | 103 | 100.6% | 88,500 | 16,456 | 122.8% |
Operating profit | 3,293 | 9,513 | 2,750 | (543) | 83.5% | 20,800 | 11,287 | 218.6% |
Ratio to net sales | 18.1% | 13.2% | 15.1% | 23.5% | ||||
Ordinary profit | 3,488 | 9,951 | 3,011 | (477) | 86.3% | 21,200 | 11,249 | 213.0% |
Ratio to net sales | 19.2% | 13.8% | 16.5% | 24.0% | ||||
Profit | 2,510 | 8,025 | 1,754 | (755) | 69.9% | 14,200 | 6,175 | 176.9% |
Ratio to net sales | 13.8% | 11.1% | 9.6% | 16.0% | ||||
Comprehensive income | 3,810 | 11,684 | 1,607 | (2,203) | 42.2% |
Capital expenditures | 205 | 2,304 | 2,014 | 1,808 | 981.8% | 3,000 | 696 | 130.2% | |
R&D Expenses | 2,600 | 12,543 | 2,998 | 397 | 115.3% | 15,700 | 3,157 | 125.2% | |
Depreciation and amortization | 639 | 2,596 | 638 | (1) | 99.8% | 2,600 | 4 | 100.2% | |
(excl. amortization of goodwill) | |||||||||
2. Consolidated Net Sales by Segment | |||||||||
(amounts are rounded down to the nearest million Yen) | |||||||||
FY2023 | FY2023 | FY2024 | Change | ||||||
1Q | 1Q | ||||||||
Amount | % | ||||||||
Pharmaceuticals, medical devices | 17,545 | 69,613 | 17,643 | 98 | 100.6% | ||||
& crop protection products | |||||||||
Real estate business | 605 | 2,430 | 611 | 5 | 101.0% | ||||
Total | 18,150 | 72,044 | 18,254 | 103 | 100.6% |
1 | KAKEN PHARMACEUTICAL CO., LTD. |
3. Sales of Main Pharmaceuticals and Medical Devices (non-consolidated)
(amounts are rounded down to the nearest million Yen)
FY2023 | FY2023 | FY2024 | Change | Plan | Change | |
1Q | 1Q | (%) | FY2024 | (%) | ||
Onychomycosis treatment | 4,667 | 17,116 | 4,495 | 96.3% | 17,200 | 100.5% |
Clenafin | ||||||
Anti-osteoarthritis agent | 4,535 | 18,040 | 4,912 | 108.3% | 19,000 | 105.3% |
Artz | ||||||
Post-operativeanti-adhesive | 1,735 | 6,995 | 1,724 | 99.4% | 6,800 | 97.2% |
Seprafilm | ||||||
Wound-healing agent | 671 | 2,626 | 626 | 93.2% | 2,600 | 99.0% |
Fiblast | ||||||
Primary axillary hyperhydrosis | ||||||
treatment | 687 | 1,812 | 681 | 99.1% | 2,200 | 121.4% |
Ecclock | ||||||
Periodontal regenerative agent | 231 | 898 | 233 | 100.7% | 900 | 100.2% |
Regroth | ||||||
Lumber disc herniation treatment | 91 | 382 | 104 | 114.0% | 400 | 104.7% |
Hernicore | ||||||
Generic products (total) | 2,013 | 7,992 | 2,062 | 102.4% | 8,100 | 101.4% |
2 | KAKEN PHARMACEUTICAL CO., LTD. |
4. Projects under Development
As of August 7, 2024
Development | Planned | Development | Remarks |
Code | Indication | Stage (*) | |
KAR | Head lice | P III | In-licensed from Arbor Pharmaceuticals, LLC. |
Product name in the US: Sklice® | |||
KP-001 | Refractory vascular | P III | Development project transferred through |
malformations | succession from ARTham Therapeutics Inc. | ||
KP-483 | Solid tumors | P I | Product discovered in-house |
(Immuno-oncology) | |||
KP-910 | Peripheral neuropathic | P I | Product discovered in-house |
pain | |||
KC-8025 | Primary biliary | P I | In-licensed from CymaBay Therapeutics, Inc. |
(Seladelpar) | cholangitis | ||
Tildacerfont | Congenital adrenal | P I | In-licensed from Spruce Biosciences, Inc. |
hyperplasia | |||
KP-001 (USA) | Refractory vascular | P I | Development project transferred through |
malformations | succession from ARTham Therapeutics Inc. | ||
(*) The development stage includes the preparation period for clinical trials. | |||
【Out-licensed overseas】 | |||
Product | Development | Out-licensed to | Indication |
Stage | |||
Clenafin (Europe) | Filed | Almirall S.A. | Onychomycosis |
Clenafin (China) | P III | AIM | Onychomycosis |
Ecclock (Korea) | Filed | Dong-Wha Pharm Co., Ltd. | Primary axillary hyperhidrosis |
【Other】 | |||
Development | Development | Developed by | Indication |
Code | Stage | ||
NM26 | P I | Johnson & Johnson | Atopic dermatitis and other indication |
3 | KAKEN PHARMACEUTICAL CO., LTD. |